SomaLogic announces SOMAscan assay deployment agreement with University College London

SomaLogic announces SOMAscan assay deployment agreement with University College London


SomaLogic announced today that it has signed an agreement with University College London (UCL) to deploy SomaLogic’s proprietary SOMAscan assay in the UCL Genomics laboratory. This agreement marks the first placement of the assay in the University of London large network of self-governing colleges and research institutes.

“The SOMAscan assay gives us a critical new tool in bringing proteomics to bear on understanding and improving personal and public health,” said Professor Juan Pablo Casas, Farr Institute at UCL .

“We are excited to apply this cutting edge technology to the many disease areas being studied here at UCL, made possible through the support of the National Institute for Health Research University College London Hospitals Biomedical Research Centre,” said Professor Aroon Hingorani, Director, UCL Institute of Cardiovascular Science.

Compared to other current proteomic technologies, SomaLogic provides researchers with unprecedented power for protein biomarker discovery, diagnostics development and pharmaceutical discovery and development. SOMAmer® (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates more than 1,300 different SOMAmer reagents, can efficiently, accurately and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.

“The placement of our SOMAscan assay at UCL is particularly gratifying to us, given both the UCL’s stellar reputation and the world-class scientists involved in overseeing this deployment,” said Byron Hewett, Chief Executive Officer of SomaLogic. “I believe that many new disease insights – and new approaches to treating those diseases – will emerge rapidly from their use of our technology.”

SomaLogic is continuing to expand research access to its SOMAscan assay through its placement in leading academic research centers worldwide. A complete list of current SOMAscan sites is on the SomaLogic web site, and additional SOMAscan assay sites will be announced over the next several months.